AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7197963
Drug: Formulation 1
RxNorm normalized name: Recombivax HB, Hepatitis B vaccine (recombinant) adult formulation 10 MCG per 1 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 1 (standard formulation)
Trial: 7197963
Drug: Formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 2 (test formulation)
Trial: 30653262
Drug: PSA screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA screening (cut-off of 4.0 ng/ml), 2-3 screening rounds offered
Trial: 28143496
Drug: Advice and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice and paracetamol
Trial: 20971822
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (40 mg/m(2)) and standard vincristine (2 mg) on day 1, followed by dexamethasone and a second cycle at day 28, reinforced by cyclophosphamide
Trial: 20971822
Drug: Continuous-infusion doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-infusion doxorubicin (12 mg/m(2)/day) and continuous-infusion vincristine (0.4 mg/day) on days 1-4
Trial: 17082518
Drug: Oral presentation
RxNorm normalized name: Gas-X Prevention Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral presentation of information in the flow chart (Group D)
Trial: 11358727
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily treatment of dithranol
Trial: 11358727
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly treatment of dithranol
Trial: 8362531
Drug: hGH (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hGH (8 IU) plus HPN (1.0-1.5 g protein/kg/day and 900 kcal/day)
Trial: 18999171
Drug: Treatment results
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment results distributed via email to collaborating institutions, with blinded recipients not notified of the subject's treatment selection.
Trial: 16043737
Drug: Low-dose parenteral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose parenteral insulin (human ultralente insulin at 0.25 units x kg(‐1) x day(‐1))
Trial: 1684872
Drug: Diazepam (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.12 mg/kg)
Trial: 1684872
Drug: Ondansetron (0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (0.24 mg/kg)
Trial: 25623462
Drug: Microecologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microecologic treatment combined enteral nutrition
Trial: 22827780
Drug: Soy nuts
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy nuts (35 g/d)
Trial: 22827780
Drug: Textured soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Textured soy protein (TSP) (35 g/d)
Trial: 19208678
Drug: PPV combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPV combined with one IVB (1.5 mg/0.06 ml) injection 2 weeks prior to surgery (BEV/PPV group)
Trial: 17205251
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% in 50 ml of saline 0.9% (Group B)
Trial: 17205251
Drug: Levobupivacaine 0.25%
RxNorm normalized name: levobupivacaine 0.25% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.25% in 40 ml of saline 0.9% (Group C)
Trial: 15140341
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg once daily for 10 days
Trial: 9702472
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ANP (2.5 pmol kg‐1 min‐1)
Trial: 9702472
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ANP (5.0 pmol kg‐1 min‐1)
Trial: 7980309
Drug: Local ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local ablative therapy
Trial: 7980309
Drug: Condom use
RxNorm normalized name: CONDOM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Condom use after ablative therapy
Trial: 2967742
Drug: Isradipine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (15 mg/day, 5 mg t.i.d.)
Trial: 2967742
Drug: Verapamil (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (240 mg/day, 80 mg t.i.d.)
Trial: 31709984
Drug: Stratified medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified medical therapy guided by invasive coronary function testing
Trial: 25974723
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplement containing whey (LNS/w)
Trial: 25974723
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplement containing soy (LNS/s)
Trial: 25974723
Drug: No lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lipid-based nutrient supplement (Control)
Trial: 25974723
Drug: CYP2B6 516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2B6 516 G>T polymorphism
Trial: 16564934
Drug: AST-120 (Kremezin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-120 (Kremezin) 0.9 g, 2.1 g, or 3.0 g, administered 3 times daily for 12 weeks
Trial: 16564934
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered 3 times daily for 12 weeks
Trial: 1536441
Drug: Intramuscular buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular buprenorphine (opioid group)
Trial: 17387123
Drug: Home-based medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based medication review by a pharmacist
Trial: 12528325
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum milk preparation (42 g per day for 2 days preoperatively)
Trial: 2527760
Drug: Oral thymoxamine
RxNorm normalized name: thymoxamine hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral thymoxamine 40 mg
Trial: 2527760
Drug: Oral thymoxamine
RxNorm normalized name: thymoxamine hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral thymoxamine 80 mg
Trial: 202985
Drug: Viloxazine 200
RxNorm normalized name: viloxazine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine 200 mg daily for 3 weeks
Trial: 202985
Drug: Viloxazine 300
RxNorm normalized name: viloxazine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine 300 mg daily for 3 weeks
Trial: 31262551
Drug: Face-to-face treatment
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face treatment (FtF)
Trial: 31262551
Drug: Chat-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chat-based treatment
Trial: 28651927
Drug: Doxorubicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin plus evofosfamide (300 mg/m2 intravenously for 30-60 min on days 1 and 8 of every 21-day cycle for up to six cycles)
Trial: 28651927
Drug: Doxorubicin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin alone (75 mg/m2 via bolus injection or continuous intravenous infusion for 6-96 h on day 1 of every 21-day cycle for up to six cycles)
Trial: 19344047
Drug: KADIAN q24h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KADIAN q24h dosing
Trial: 19344047
Drug: KADIAN q12h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KADIAN q12h dosing
Trial: 19344047
Drug: KADIAN q12h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KADIAN q12h dosing after switch
Trial: 11144399
Drug: Amoxicillin/CA 13.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/CA 13.3 mg/kg t.i.d.
Trial: 9134599
Drug: BCG therapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG therapy (120 mg in 50 mL saline, 5 x 10^7 viable organisms), weekly for 6 weeks after TUR
Trial: 31362537
Drug: MBB coaching
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBB coaching (treatment)
Trial: 21053789
Drug: Integrated dementia
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated dementia intervention (cognitive stimulation training, exercise, music, art, and horticultural therapy)
Trial: 15480814
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg/day (escalating to 10 mg after 1 month) and vitamin E 1,000 IU/day
Trial: 12078939
Drug: Non-tapering prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-tapering prednisolone (40 mg/day for 8 days)
Trial: 12078939
Drug: Tapering prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapering prednisolone (40 mg tapering by 5 mg/day for 8 days)
Trial: 9698776
Drug: Sublingual propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual propranolol (40 mg)
Trial: 9698776
Drug: Peroral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroral propranolol (40 mg)
Trial: 7608665
Drug: Apomorphine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (mean dose 3.4 mg, range 0.8-6.0 mg)
Trial: 30629187
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) initiated in HIV-infected adults
Trial: 30934797
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g PGX granules (PGXG)
Trial: 26306332
Drug: Florfenicol at
RxNorm normalized name: Florfenicol
DrugBank: Florfenicol (DB11413)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Florfenicol at 10 mg/kg (medicated feed)
Trial: 26306332
Drug: Unmedicated feed
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmedicated feed (0 mg/kg)
Trial: 19295645
Drug: Tinidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (2 g) + Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
Trial: 19295645
Drug: Tinidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (2 g) + Placebo
Trial: 11208725
Drug: Intravenous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous octreotide 50 microg
Trial: 11208725
Drug: Intravenous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous octreotide 500 microg
Trial: 11208725
Drug: Intravenous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous octreotide 50 microg bolus followed by continuous infusion of 50 microg/h
Trial: 11208725
Drug: Intravenous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous octreotide 250 microg/h continuous infusion
Trial: 11208725
Drug: Repeated 50
RxNorm normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated 50 microg injections of octreotide after an initial bolus
Trial: 11208725
Drug: Placebo bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bolus and continuous octreotide infusion (50 microg/h)
Trial: 7929833
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion during fasting (n = 6)
Trial: 7929833
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion during euglycemic insulin clamp (n = 8)
Trial: 7929833
Drug: Control forearm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control forearm during euglycemic insulin clamp
Trial: 7929833
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion in one forearm during euglycemic insulin clamp
Trial: 3129445
Drug: Naloxone (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.08 mg/kg BW, iv)
Trial: 30297240
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy regimens (folinic acid, fluorouracil, and oxaliplatin or fluorouracil, leucovorin, and irinotecan, with or without cetuximab)
Trial: 16844625
Drug: Plasma levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma levels of TNF‐alpha rose more than 20 pg/mL during and after standard CPB in 13 patients (group 1)
Trial: 16844625
Drug: Plasma levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma levels of TNF‐alpha were less than 20 pg/mL in the remaining 7 patients (group 2)
Trial: 12727963
Drug: Low-dose GH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose GH (Genotropin 0.4 mg/d) for 8 months
Trial: 10969256
Drug: Botulinum-A toxin
RxNorm normalized name: Botulinum A neurotoxin
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum-A toxin (BTA) injection plus occupational therapy
Trial: 2003499
Drug: Medication profile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication profile review by a clinical pharmacist
Trial: 2003499
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medication profile review)
Trial: 26657482
Drug: Spray application
RxNorm normalized name: Inhalation Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray application of fluoride mouthwash (0.05% NaF; 226-ppm fluoride)
Trial: 21128879
Drug: dalcetrapib 600
RxNorm normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dalcetrapib 600 mg/day
Trial: 17389338
Drug: Fludarabine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (25 mg/m2/d for 5 days IV, repeated every 28 days)
Trial: 17389338
Drug: Fludarabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine plus cyclophosphamide (FC) (fludarabine 30 mg/m2/d for 3 days IV plus cyclophosphamide 250 mg/m2/d for 3 days, repeated every 28 days)
Trial: 16344188
Drug: Sutter implant
RxNorm normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutter implant replacement arthroplasty
Trial: 16344188
Drug: Swanson implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swanson implant replacement arthroplasty
Trial: 16540800
Drug: MMN (iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMN (iron 12.5 mg + folic acid 150 microg + zinc 5 mg)
Trial: 16540800
Drug: FFA (iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFA (iron 12.5 mg + folic acid 150 microg)
Trial: 8878221
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin A (50,000 to 200,000 IU of retinyl palmitate, doses according to age; n = 89)
Trial: 8878221
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin A (for subgroup with significant hypoxemia)
Trial: 1512341
Drug: Hydrochlorothiazide and
RxNorm normalized name: hydrochlorothiazide and potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide and amiloride (50 + 5 mg)
Trial: 1512341
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (19 +/- 1 mg/24 h)
Trial: 6421013
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg three times a day for 1 week
Trial: 29966038
Drug: Roxadustat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (100 mg) under fed conditions
Trial: 29966038
Drug: Roxadustat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (100 mg) under fasted conditions
Trial: 29966038
Drug: Roxadustat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (100 mg) with SCA
Trial: 29966038
Drug: Roxadustat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (100 mg) alone
Trial: 30358565
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose oseltamivir (SD)
Trial: 30358565
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose oseltamivir (DD)
Trial: 27041244
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day rosuvastatin (R group, n=26)
Trial: 27041244
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day rosuvastatin plus 2 g/day of ω-3 PUFAs (R+O group, n=24)
Trial: 24928218
Drug: Directly observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly observed varenicline therapy
Trial: 24928218
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (self-administered varenicline)
Trial: 22010847
Drug: Agaricus blazei
RxNorm normalized name: AGARICUS BLAZEI WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agaricus blazei Murrill (AbM) dry extract, 900 mg/day for 60 days
Trial: 20467879
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine administered for 60 min
Trial: 8626261
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dosing (6 mg/kg)
Trial: 8626261
Drug: Thrice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice daily dosing (6 mg/kg)
Trial: 30946860
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg cortisol
Trial: 15353142
Drug: Norethisterone oenanthate
RxNorm normalized name: Oenanthic acid
DrugBank: Norethindrone enanthate (DB14678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone oenanthate (NET EN) 200 mg used as a 2‐monthly injection
Trial: 9599191
Drug: Protein supplementation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplementation, 20 g/d
Trial: 8023348
Drug: Nimodipine 120
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine 120 mg/d PO for 21 days
Trial: 2661606
Drug: Benztropine 4
RxNorm normalized name: benztropine 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benztropine 4 mg/day
Trial: 28988240
Drug: Intensive 1-year
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive 1-year lifestyle treatment with 2 months inpatient period (short-stay group)
Trial: 28988240
Drug: Intensive 1-year
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive 1-year lifestyle treatment with 6 months inpatient period (long-stay group)
Trial: 28988240
Drug: Short-stay treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-stay treatment
Trial: 28988240
Drug: Long-stay treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-stay treatment
Trial: 24076103
Drug: 2% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine digluconate solution applied for 30s after etching
Trial: 21518686
Drug: RenalGuard System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RenalGuard System treatment
Trial: 18356834
Drug: Standard group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group-based behavioral treatment
Trial: 4038550
Drug: Intravenous droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous droperidol
Trial: 8618770
Drug: 0.02% (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02% (0.2 mg/ml) mitomycin C for 5 minutes
Trial: 6398861
Drug: Halopemide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halopemide (2 X 10 mg/day)
Trial: 6398861
Drug: Halopemide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halopemide (2 X 20 mg/day)
Trial: 23859303
Drug: amlodipine/benazepril 2.5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine/benazepril 2.5/10 mg
Trial: 23859303
Drug: amlodipine/benazepril 5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine/benazepril 5/10 mg
Trial: 23859303
Drug: benazepril 10
RxNorm normalized name: benazepril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril 10 mg
Trial: 23497111
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (methotrexate + sulfasalazine + hydroxychloroquine)
Trial: 12241634
Drug: Partial median
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial median and ulnar nerve transfer; specific details on dosage and duration not available.
Trial: 12241634
Drug: Phrenic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phrenic and spinal accessary nerve transfer; specific details on dosage and duration not available.